 Daniel Pastula
Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 9 | 2018 | 172 | 1.890 |
Why?
| | Encephalitis, California | 4 | 2019 | 9 | 1.650 |
Why?
| | Epilepsy | 7 | 2024 | 390 | 1.450 |
Why?
| | Guillain-Barre Syndrome | 5 | 2017 | 23 | 1.350 |
Why?
| | Encephalitis, Tick-Borne | 3 | 2023 | 8 | 1.260 |
Why?
| | Flavivirus Infections | 2 | 2019 | 9 | 1.220 |
Why?
| | Amyotrophic Lateral Sclerosis | 6 | 2015 | 96 | 1.180 |
Why?
| | Disease Outbreaks | 8 | 2023 | 419 | 1.180 |
Why?
| | Central Nervous System Diseases | 2 | 2023 | 74 | 1.140 |
Why?
| | Bunyaviridae Infections | 3 | 2019 | 15 | 1.140 |
Why?
| | Monkeypox virus | 3 | 2023 | 23 | 1.100 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 265 | 1.070 |
Why?
| | Nervous System Diseases | 4 | 2023 | 286 | 1.000 |
Why?
| | Meningitis | 2 | 2023 | 80 | 0.900 |
Why?
| | Chikungunya Fever | 2 | 2017 | 82 | 0.900 |
Why?
| | Encephalitis | 3 | 2023 | 142 | 0.870 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.790 |
Why?
| | Arbovirus Infections | 2 | 2023 | 20 | 0.780 |
Why?
| | Smallpox Vaccine | 1 | 2023 | 23 | 0.770 |
Why?
| | Neurology | 3 | 2024 | 117 | 0.770 |
Why?
| | Flavivirus | 2 | 2019 | 19 | 0.750 |
Why?
| | Optic Neuritis | 1 | 2023 | 44 | 0.750 |
Why?
| | Encephalomyelitis | 1 | 2022 | 14 | 0.740 |
Why?
| | Encephalitis Virus, California | 3 | 2019 | 6 | 0.720 |
Why?
| | Phlebovirus | 3 | 2020 | 6 | 0.720 |
Why?
| | Exanthema | 1 | 2022 | 86 | 0.700 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 110 | 0.690 |
Why?
| | Creatine | 2 | 2012 | 63 | 0.670 |
Why?
| | Neuroprotective Agents | 2 | 2012 | 149 | 0.620 |
Why?
| | Acyclovir | 1 | 2020 | 98 | 0.620 |
Why?
| | Encephalomyelitis, Eastern Equine | 1 | 2019 | 5 | 0.610 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 29 | 0.590 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 339 | 0.560 |
Why?
| | Thrombocytopenia | 2 | 2017 | 204 | 0.550 |
Why?
| | Hepatitis E | 1 | 2017 | 2 | 0.500 |
Why?
| | Hepatitis E virus | 1 | 2017 | 2 | 0.500 |
Why?
| | Myelitis | 4 | 2021 | 107 | 0.500 |
Why?
| | Epidemiological Monitoring | 1 | 2017 | 70 | 0.490 |
Why?
| | Communicable Diseases, Emerging | 1 | 2016 | 39 | 0.460 |
Why?
| | Dengue | 1 | 2016 | 91 | 0.440 |
Why?
| | Antiviral Agents | 1 | 2020 | 769 | 0.420 |
Why?
| | Ixodidae | 1 | 2014 | 7 | 0.410 |
Why?
| | West Nile Fever | 2 | 2026 | 57 | 0.410 |
Why?
| | Humans | 52 | 2026 | 145785 | 0.410 |
Why?
| | Zika Virus | 5 | 2018 | 136 | 0.390 |
Why?
| | Enterovirus Infections | 3 | 2021 | 173 | 0.340 |
Why?
| | Critical Care | 1 | 2017 | 702 | 0.330 |
Why?
| | Meningoencephalitis | 2 | 2021 | 24 | 0.320 |
Why?
| | Homosexuality, Male | 2 | 2022 | 231 | 0.320 |
Why?
| | Male | 26 | 2026 | 73012 | 0.260 |
Why?
| | Fatal Outcome | 4 | 2018 | 305 | 0.260 |
Why?
| | Muscle Hypotonia | 2 | 2018 | 34 | 0.260 |
Why?
| | Immunoglobulin M | 2 | 2026 | 265 | 0.250 |
Why?
| | United States | 11 | 2024 | 16126 | 0.250 |
Why?
| | Infant | 9 | 2022 | 10091 | 0.250 |
Why?
| | Population Surveillance | 4 | 2018 | 484 | 0.250 |
Why?
| | North America | 2 | 2019 | 304 | 0.250 |
Why?
| | Motor Neuron Disease | 3 | 2012 | 20 | 0.250 |
Why?
| | West Nile virus | 1 | 2026 | 41 | 0.230 |
Why?
| | Culicidae | 2 | 2016 | 33 | 0.230 |
Why?
| | Child, Preschool | 8 | 2022 | 11868 | 0.230 |
Why?
| | Enterovirus D, Human | 2 | 2016 | 87 | 0.210 |
Why?
| | Animals | 11 | 2023 | 38106 | 0.200 |
Why?
| | Rituximab | 2 | 2023 | 210 | 0.200 |
Why?
| | Infant, Newborn | 4 | 2022 | 6465 | 0.200 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2023 | 122 | 0.200 |
Why?
| | Child | 10 | 2022 | 22740 | 0.200 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2023 | 31 | 0.200 |
Why?
| | Middle Aged | 13 | 2026 | 36309 | 0.190 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 55 | 0.190 |
Why?
| | Encephalitis, Viral | 1 | 2023 | 45 | 0.190 |
Why?
| | District of Columbia | 1 | 2022 | 38 | 0.190 |
Why?
| | Adolescent | 11 | 2024 | 22577 | 0.180 |
Why?
| | Guideline Adherence | 1 | 2026 | 587 | 0.170 |
Why?
| | Enterovirus A, Human | 1 | 2021 | 13 | 0.170 |
Why?
| | Adult | 13 | 2026 | 40882 | 0.170 |
Why?
| | Health Surveys | 2 | 2024 | 520 | 0.170 |
Why?
| | Age of Onset | 2 | 2015 | 557 | 0.160 |
Why?
| | Acute Disease | 4 | 2018 | 1036 | 0.160 |
Why?
| | Vital Capacity | 2 | 2012 | 292 | 0.160 |
Why?
| | Young Adult | 7 | 2024 | 14254 | 0.160 |
Why?
| | Education, Medical | 1 | 2024 | 276 | 0.160 |
Why?
| | Registries | 1 | 2009 | 2410 | 0.160 |
Why?
| | Antibodies, Viral | 5 | 2026 | 674 | 0.160 |
Why?
| | Hashimoto Disease | 1 | 2020 | 10 | 0.160 |
Why?
| | Colorado | 3 | 2022 | 4556 | 0.160 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2021 | 78 | 0.160 |
Why?
| | Simplexvirus | 1 | 2020 | 82 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 784 | 0.150 |
Why?
| | Aged | 11 | 2026 | 26217 | 0.150 |
Why?
| | Disease Progression | 4 | 2012 | 2865 | 0.150 |
Why?
| | Bunyamwera virus | 1 | 2019 | 3 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2020 | 172 | 0.150 |
Why?
| | Incidence | 5 | 2018 | 2934 | 0.150 |
Why?
| | Comorbidity | 1 | 2024 | 1662 | 0.150 |
Why?
| | Neuromuscular Diseases | 1 | 2021 | 145 | 0.140 |
Why?
| | Central Nervous System Infections | 1 | 2019 | 35 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2021 | 260 | 0.140 |
Why?
| | Stem Cells | 1 | 2023 | 630 | 0.140 |
Why?
| | Immunoglobulin G | 1 | 2023 | 892 | 0.140 |
Why?
| | Autopsy | 2 | 2015 | 94 | 0.140 |
Why?
| | La Crosse virus | 1 | 2017 | 4 | 0.130 |
Why?
| | Motor Disorders | 1 | 2018 | 17 | 0.130 |
Why?
| | Seizures | 1 | 2022 | 485 | 0.130 |
Why?
| | Skin | 1 | 2022 | 754 | 0.130 |
Why?
| | Micronesia | 1 | 2017 | 8 | 0.130 |
Why?
| | Fever | 2 | 2017 | 320 | 0.130 |
Why?
| | Female | 17 | 2026 | 79045 | 0.130 |
Why?
| | Veterans | 1 | 2009 | 1642 | 0.130 |
Why?
| | Encephalomyelitis, Equine | 1 | 2016 | 3 | 0.130 |
Why?
| | Encephalitis Virus, Eastern Equine | 1 | 2016 | 5 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 2 | 2023 | 3916 | 0.120 |
Why?
| | Fiji | 1 | 2016 | 2 | 0.120 |
Why?
| | Pandemics | 2 | 2023 | 1711 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2017 | 150 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2012 | 1752 | 0.120 |
Why?
| | Diagnostic Errors | 1 | 2017 | 178 | 0.120 |
Why?
| | Arthropod Vectors | 1 | 2016 | 7 | 0.120 |
Why?
| | Neurologic Examination | 1 | 2016 | 132 | 0.120 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2016 | 8 | 0.120 |
Why?
| | Ticks | 1 | 2016 | 30 | 0.120 |
Why?
| | Thogotovirus | 1 | 2015 | 1 | 0.110 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1998 | 0.110 |
Why?
| | Lyme Disease | 1 | 2015 | 58 | 0.110 |
Why?
| | Chikungunya virus | 1 | 2016 | 81 | 0.110 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 280 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2017 | 8347 | 0.110 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2018 | 440 | 0.100 |
Why?
| | Plant Oils | 1 | 2013 | 33 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2014 | 501 | 0.100 |
Why?
| | Linear Models | 1 | 2015 | 849 | 0.090 |
Why?
| | Puerto Rico | 3 | 2017 | 63 | 0.090 |
Why?
| | Models, Statistical | 1 | 2017 | 672 | 0.090 |
Why?
| | Age Factors | 2 | 2018 | 3346 | 0.090 |
Why?
| | Quality of Life | 2 | 2022 | 3211 | 0.090 |
Why?
| | Curriculum | 1 | 2019 | 1074 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1082 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2016 | 3634 | 0.090 |
Why?
| | Health Promotion | 1 | 2017 | 775 | 0.080 |
Why?
| | Multiple Sclerosis | 1 | 2015 | 489 | 0.080 |
Why?
| | Vietnam | 1 | 2009 | 27 | 0.080 |
Why?
| | Emergency Service, Hospital | 1 | 2022 | 2383 | 0.080 |
Why?
| | Muscle Cramp | 1 | 2009 | 7 | 0.080 |
Why?
| | Hospitalization | 2 | 2017 | 2461 | 0.070 |
Why?
| | Piracetam | 1 | 2009 | 14 | 0.070 |
Why?
| | Alzheimer Disease | 1 | 2015 | 630 | 0.070 |
Why?
| | Parkinson Disease | 1 | 2015 | 601 | 0.070 |
Why?
| | Influenza, Human | 1 | 2015 | 624 | 0.070 |
Why?
| | Muscle Spasticity | 1 | 2009 | 63 | 0.070 |
Why?
| | Dietary Supplements | 1 | 2013 | 584 | 0.070 |
Why?
| | RNA, Viral | 2 | 2026 | 693 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 971 | 0.060 |
Why?
| | Anticonvulsants | 1 | 2009 | 246 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1330 | 0.060 |
Why?
| | United States Department of Veterans Affairs | 1 | 2009 | 779 | 0.050 |
Why?
| | Prevalence | 2 | 2024 | 2875 | 0.050 |
Why?
| | Brain | 1 | 2017 | 2969 | 0.050 |
Why?
| | Survival Rate | 1 | 2009 | 2094 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2026 | 979 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2008 | 1062 | 0.050 |
Why?
| | Astrocytes | 1 | 2023 | 228 | 0.040 |
Why?
| | Eosinophils | 1 | 2023 | 316 | 0.040 |
Why?
| | Cross Reactions | 1 | 2020 | 130 | 0.040 |
Why?
| | Microspheres | 1 | 2020 | 142 | 0.040 |
Why?
| | Immunoassay | 1 | 2020 | 109 | 0.040 |
Why?
| | Antigens, Viral | 1 | 2020 | 182 | 0.040 |
Why?
| | Inpatients | 1 | 2024 | 553 | 0.040 |
Why?
| | Chronic Disease | 1 | 2024 | 1812 | 0.030 |
Why?
| | Missouri | 1 | 2018 | 66 | 0.030 |
Why?
| | Epilepsia Partialis Continua | 1 | 2017 | 3 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2023 | 872 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 198 | 0.030 |
Why?
| | Epilepsy, Generalized | 1 | 2017 | 24 | 0.030 |
Why?
| | Ohio | 1 | 2017 | 146 | 0.030 |
Why?
| | Paraplegia | 1 | 2017 | 60 | 0.030 |
Why?
| | Delphi Technique | 1 | 2019 | 333 | 0.030 |
Why?
| | Insurance, Major Medical | 1 | 2017 | 2 | 0.030 |
Why?
| | Communication | 1 | 2024 | 977 | 0.030 |
Why?
| | Arkansas | 1 | 2016 | 23 | 0.030 |
Why?
| | Muscle Weakness | 1 | 2017 | 92 | 0.030 |
Why?
| | Medical Records | 1 | 2017 | 192 | 0.030 |
Why?
| | Microcephaly | 1 | 2018 | 104 | 0.030 |
Why?
| | Epilepsies, Partial | 1 | 2017 | 63 | 0.030 |
Why?
| | Serologic Tests | 1 | 2016 | 54 | 0.030 |
Why?
| | Serogroup | 1 | 2016 | 45 | 0.030 |
Why?
| | Headache | 1 | 2017 | 151 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2018 | 202 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2017 | 148 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1509 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 83 | 0.030 |
Why?
| | Long-Term Care | 1 | 2017 | 118 | 0.030 |
Why?
| | Spasms, Infantile | 1 | 2017 | 138 | 0.030 |
Why?
| | Geographic Mapping | 1 | 2015 | 26 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2016 | 133 | 0.030 |
Why?
| | Kansas | 1 | 2015 | 27 | 0.030 |
Why?
| | Self-Management | 1 | 2018 | 204 | 0.030 |
Why?
| | Forecasting | 1 | 2017 | 390 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1428 | 0.030 |
Why?
| | Electroencephalography | 1 | 2017 | 563 | 0.030 |
Why?
| | Pregnancy | 2 | 2018 | 7216 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2026 | 17330 | 0.020 |
Why?
| | Coconut Oil | 1 | 2013 | 4 | 0.020 |
Why?
| | Neurodegenerative Diseases | 1 | 2015 | 143 | 0.020 |
Why?
| | Genome, Viral | 1 | 2015 | 214 | 0.020 |
Why?
| | Public Health | 1 | 2018 | 574 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2013 | 37 | 0.020 |
Why?
| | Phylogeny | 1 | 2015 | 917 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1491 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1247 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 193 | 0.020 |
Why?
| | Review Literature as Topic | 1 | 2008 | 52 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2016 | 11794 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2770 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1925 | 0.010 |
Why?
| | Data Collection | 1 | 2008 | 643 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6085 | 0.010 |
Why?
| | Time Factors | 1 | 2016 | 7134 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4302 | 0.010 |
Why?
| | Risk Factors | 1 | 2018 | 10919 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1898 | 0.010 |
Why?
| | Research Design | 1 | 2008 | 1139 | 0.010 |
Why?
| | Biomedical Research | 1 | 2008 | 719 | 0.010 |
Why?
|
|
Pastula's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|